Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
19 hedge funds and large institutions have $1.84M invested in Interpace Biosciences, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
19% more capital invested
Capital invested by funds: $1.54M → $1.84M (+$291K)
6% more funds holding
Funds holding: 18 → 19 (+1)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.2K |
| 2 |
Renaissance Technologies
New York
|
+$1.09K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$753 |
| 4 |
Morgan Stanley
New York
|
+$38 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$38.9K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$903 |
| 5 |
Goldman Sachs
New York
|
-$565 |
IDXG Hedge Fund Activity: Q2 2016 in Review
19 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2016, worth a combined $1.84M — up 19% from $1.54M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IDXG positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $18.2K. The largest seller was Dimensional Fund Advisors, cutting an estimated $38.9K.
- 19 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2016, up from 18 in Q1 2016.
- Funds reported $1.84M of Interpace Biosciences, Inc. Common Stock stock for Q2 2016, up 19% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2016 and 2 closed out, a net change of +1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2016 was Citadel Advisors, an estimated $18.2K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2016 was Dimensional Fund Advisors, an estimated $38.9K sold.
Based on aggregated 13F filings for Q2 2016.